Stocktoria
BioXcel Therapeutics, Inc. BTAI
BioXcel Therapeutics, Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $642,000 | $2.3M | $1.4M | $375,000 | — | — | — | — | — |
| R&D expense | $30.3M | $30.4M | $84.3M | $91.2M | $52.7M | $58.0M | $25.8M | $14.6M | $2.7M |
| SG&A expense | $20.5M | $34.5M | $83.4M | $68.8M | $54.2M | — | — | — | — |
| Operating income | -$50.5M | -$67.2M | -$171.8M | -$159.6M | -$106.9M | -$82.3M | -$33.6M | -$20.0M | -$4.5M |
| Interest expense | — | — | $13.3M | $8.2M | $40,000 | $27,000 | $20,000 | — | — |
| Income tax | $0 | $0 | $0 | — | — | — | — | — | — |
| Net income | -$69.9M | -$59.6M | -$179.1M | -$165.8M | -$106.9M | -$82.2M | -$33.0M | -$19.3M | -$4.5M |
| EPS (diluted) | $-5.73 | $-23.51 | $-98.33 | $-5.92 | $-4.05 | $-3.79 | — | — | — |
| Operating cash flow | -$57.6M | -$72.0M | -$155.0M | -$135.3M | -$82.2M | -$66.3M | -$27.1M | -$13.5M | -$2.2M |
| Free cash flow | -$57.6M | -$72.0M | -$155.0M | -$135.5M | -$82.6M | -$66.7M | -$28.0M | -$13.8M | — |
| Cash & equivalents | $28.4M | $29.9M | $65.2M | $193.7M | $233.0M | $213.1M | $32.4M | $42.6M | $887,000 |
| Inventory | $722,000 | $679,000 | $2.0M | $2.0M | — | — | — | — | — |
| Total assets | $44.9M | $38.3M | $73.7M | $205.9M | $239.4M | $219.9M | $36.4M | $43.5M | $1.4M |
| Total liabilities | $140.4M | $131.4M | $130.2M | $129.1M | $17.8M | $13.2M | $9.5M | $4.7M | $2.3M |
| Shareholders' equity | -$95.5M | -$93.1M | -$56.5M | $76.8M | $221.7M | $206.7M | $26.9M | $38.9M | -$982,000 |
Growth · year-over-year · Revenue CAGR 19.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -71.7% | +64.2% | +268.0% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.